469 - Improved synthesis of [18F]fluoro-d2-methyl tosylate suitable for automated pharmaceutical labeling (ID 342) - Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting

469 - Improved synthesis of [¹⁸F]fluoro-d₂-methyl tosylate suitable for automated pharmaceutical labeling (ID 342)

Molecular Targeting Probes - Radioactive & Nonradioactive -> Radiopharmacy 469

469 - Improved synthesis of [¹⁸F]fluoro-d₂-methyl tosylate suitable for automated pharmaceutical labeling (ID 342)

Session Name

Radiopharmacy

Speakers

J. Wang

Authors

Presentation Topic

Molecular Targeting Probes - Radioactive & Nonradioactive -> Radiopharmacy

Presentation Number

469

Previous Eposter

468 - Production of [⁸⁹Zr]Oxinate₄and cell labelingfor human use (ID 343)

Next Eposters

470 - Radiosynthesis of [¹⁸F]-flumazenil and its clinical utilization. (ID 341)

471 - Synthesis and preclinical evaluation of a molecular probe for imaging lung cancer with L858R/T790M mutation of epidermal growth factor receptor (EGFR) (ID 340)

472 - Histopathologic correlation with ⁶⁸Ga PSMA PET/CT in Non Prostate Tumors. (ID 522)

473 - Clinical Application of SPECT-CT Imaging with 99mTc/PSMA T4 in patients with Recurrent Prostate Cancer (ID 523)

474 - A Pilot Study on 68Ga-PSMA-11 PET/CT in Assessing Metastatic Clear Cell Renal Cell Carcinoma (ID 521)

475 - 68Ga-PSMA PET/MRI for the Diagnoses of Primary and Biochemical Recurrent Prostate Cancer: A System Review and Meta-Analysis (ID 520)

477 - [¹⁸F]DCFPyL associated radioactivity in patient saliva samples. (ID 527)

484 - Imaging characteristics and diagnostic performance of ¹⁸F-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy (ID 547)

486 - ¹⁸F-FDG PET/CT in prognostication of malignant peripheral nerve sheath tumors. (ID 551)

487 - Prognostic and predictive interest of ¹⁸F-FDG PET/CT in the initial assessment of stage III B-C-D and IV patients with melanoma before anti-PD-1 immunotherapy. (ID 545)